Literature DB >> 26965693

Pathogenic Role of Serine Protease HtrA2/Omi in Neurodegenerative Diseases.

Hui-Gwan Goo1, Hyangshuk Rhim2, Seongman Kang3.   

Abstract

High-temperature-requirement A2 (HtrA2)/Omi/PARK13 is a serine protease with extensive homology to the Escherichia coli HtrAs that are required for bacterial survival at high temperatures. The HtrA2 protein is a key modulator of mitochondrial molecular quality control but under stressful conditions it is released into the cytosol, where it promotes cell death by various pathways, including caspase-dependent pathway and ER stress-mediated apoptosis. Recently, the HtrA2 protein has received great attention for its potential role in neurodegeneration. Here, we review the current knowledge and pathophysiological functions of the HtrA2 protein in neurodegenerative disorders such as Parkinson's and Alzheimer's disease. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Alzheimer's disease; HtrA2; HtrA2 interacting proteins; Parkinson’s disease; apoptosis; mitochondria; protein qualityzzm321990control

Mesh:

Substances:

Year:  2017        PMID: 26965693     DOI: 10.2174/1389203717666160311115750

Source DB:  PubMed          Journal:  Curr Protein Pept Sci        ISSN: 1389-2037            Impact factor:   3.272


  7 in total

1.  Serine protease HtrA2/Omi regulates adaptive mitochondrial reprogramming in the brain cortex after ischemia/reperfusion injury via UCP2-SIRT3-PGC1 axis.

Authors:  Hao Meng; Lian-Kun Sun; Jing Su; Wan-Yu Yan; Yao Jin; Xin Luo; Xian-Rui Jiang; Hong-Lei Wang
Journal:  Hum Cell       Date:  2021-11-22       Impact factor: 4.174

2.  Specific knockdown of Htra2 by CRISPR-CasRx prevents acquired sensorineural hearing loss in mice.

Authors:  Yang Guo; Lei Han; Shuang Han; Honghai Tang; Shengyi Wang; Chong Cui; Bing Chen; Huawei Li; Yilai Shu
Journal:  Mol Ther Nucleic Acids       Date:  2022-04-26       Impact factor: 10.183

3.  Synthetic Polyclonal-Derived CDR Peptides as an Innovative Strategy in Glaucoma Therapy.

Authors:  Carsten Schmelter; Kristian Nzogang Fomo; Natarajan Perumal; Caroline Manicam; Katharina Bell; Norbert Pfeiffer; Franz H Grus
Journal:  J Clin Med       Date:  2019-08-15       Impact factor: 4.241

4.  Allosteric inhibition of HTRA1 activity by a conformational lock mechanism to treat age-related macular degeneration.

Authors:  Stefan Gerhardy; Mark Ultsch; Wanjian Tang; Evan Green; Jeffrey K Holden; Wei Li; Alberto Estevez; Chris Arthur; Irene Tom; Alexis Rohou; Daniel Kirchhofer
Journal:  Nat Commun       Date:  2022-09-05       Impact factor: 17.694

5.  Inhibition of High-Temperature Requirement Protein A2 Protease Activity Represses Myogenic Differentiation via UPRmt.

Authors:  Hongyu Sun; Luyan Shen; Ping Zhang; Fu Lin; Jiaoyan Ma; Ying Wu; Huimei Yu; Liankun Sun
Journal:  Int J Mol Sci       Date:  2022-10-04       Impact factor: 6.208

6.  Over-activation of a nonessential bacterial protease DegP as an antibiotic strategy.

Authors:  Hyunjin Cho; Yuri Choi; Kyungjin Min; Jung Bae Son; Hyojin Park; Hyung Ho Lee; Seokhee Kim
Journal:  Commun Biol       Date:  2020-10-01

7.  Chiral Interface of Amyloid Beta (Aβ): Relevance to Protein Aging, Aggregation and Neurodegeneration.

Authors:  Victor V Dyakin; Thomas M Wisniewski; Abel Lajtha
Journal:  Symmetry (Basel)       Date:  2020-04-07       Impact factor: 2.713

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.